Genetic and molecular functional characterization of variants within TNFSF13B, a positional candidate preeclampsia susceptibility gene on 13q

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Fenstad, Mona H ^a   Johnson, Matthew P ^b   Roten, Linda T ^a   Aas, Per A ^a   Forsmo, Siri ^a   Klepper, Kjetil ^a   East, Christine E ^c   Abraham, Lawrence J ^d   Blangero, John ^b   Brennecke, Shaun P ^c   Austgulen, Rigmor ^a   Moses, Eric K ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; GENOMIC DNA; OCTAMER TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR YY1;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; ALLELE; ARTICLE; AUSTRALIA; CHROMOSOME 13Q; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HUMAN; MOLECULAR DYNAMICS; NEW ZEALAND; NUCLEOTIDE SEQUENCE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY OUTCOME; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL BIOINFORMATICS; TRANSCRIPTION INITIATION SITE;

AUSTRALIA; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 13; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; NORWAY; POLYMORPHISM, SINGLE NUCLEOTIDE; PRE-ECLAMPSIA; PREGNANCY;

EID: 77958524815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012993     Document Type: Article

References (85)

1. Wallis AB, Saftlas AF, Hsia J, Atrash HK (2008) Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 21: 521-526.
2. Ness RB, Roberts JM (1996) Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 175: 1365-1370.
3. Roberts JM, Gammill HS (2005) Preeclampsia: recent insights. Hypertension 46: 1243-1249.
4. Brosens IA, Robertson WB, Dixon HG (1972) The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1: 177-191.
5. Huppertz B (2008) Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 51: 970-975.
6. Saito S, Nakashima A, Shima T, Ito M (2010) Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 63(6): 601-10.
7. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, et al. (2000) Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 157: 2111-2122.
8. Redman CW, Sargent IL (2010) Immunology of Pre-Eclampsia. Am J Reprod Immunol 63(6): 534-43.
9. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P (2004) Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. Am J Med Genet A 130: 365-371.
10. Dekker G, Robillard PY (2007) Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update. J Reprod Immunol 76: 8-16.
11. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, et al. (2001) Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 344: 867-872.
12. Li DK, Wi S (2000) Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol 151: 57-62.
13. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, et al. (1998) Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 316: 1343-1347.
14. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, et al. (2005) Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ 331: 877.
15. Chappell S, Morgan L (2006) Searching for genetic clues to the causes of preeclampsia. Clin Sci (Lond) 110: 443-458.
16. Laivuori H (2007) Genetic aspects of preeclampsia. Front Biosci 12: 2372-2382.
17. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W (2008) Genes and the preeclampsia syndrome. J Perinat Med 36: 38-58.
18. Arngrimsson R, Sigurard TS, Frigge ML, Bjarnadottir RI, Jonsson T, et al. (1999) A genome-wide scan reveals a maternal susceptibility locus for preeclampsia on chromosome 2p13. Hum Mol Genet 8: 1799-1805.
19. Harrison GA, Humphrey KE, Jones N, Badenhop R, Guo G, et al. (1997) A genomewide linkage study of preeclampsia/eclampsia reveals evidence for a candidate region on 4q. Am J Hum Genet 60: 1158-1167.
20. Johnson MP, Fitzpatrick E, Dyer TD, Jowett JB, Brennecke SP, et al. (2007) Identification of two novel quantitative trait loci for pre-eclampsia susceptibility on chromosomes 5q and 13q using a variance components-based linkage approach. Mol Hum Reprod 13: 61-67.
21. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, et al. Eur J Hum Genet 9: 758-764.
22. Laivuori H, Lahermo P, Ollikainen V, Widen E, Haiva-Mallinen L, et al. (2003) Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 72: 168-177.
23. Moses EK, Lade JA, Guo G, Wilton AN, Grehan M, et al. (2000) A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 67: 1581-1585.
24. Moses EK, Fitzpatrick E, Freed KA, Dyer TD, Forrest S, et al. (2006) Objective prioritization of positional candidate genes at a quantitative trait locus for preeclampsia on 2q22. Mol Hum Reprod 12: 505-512.
25. Fitzpatrick E, Goring HH, Liu H, Borg A, Forrest S, et al. (2004) Fine mapping and SNP analysis of positional candidates at the preeclampsia susceptibility locus (PREG1) on chromosome 2. Hum Biol 76: 849-862.
26. Fitzpatrick E, Johnson MP, Dyer TD, Forrest S, Elliott K, et al. (2009) Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Hum Reprod 15: 195-204.
27. Roten LT, Johnson MP, Forsmo S, Fitzpatrick E, Dyer TD, et al. (2009) Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet 17: 250-257.
28. Johnson MP, Roten LT, Dyer TD, East CE, Forsmo S, et al. (2009) The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations. Hum Genet 126: 655-666.
29. Roten LT (2009) Genetic predisposition for development of preeclampsia - candidate gene studies in the HUNT (Nord-Trøndelag Health Study) population [dissertation]. Norwegian University of Science and Technology. 126 p.
30. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
31. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
32. Chang SK, Arendt BK, Darce JR, Wu X, Jelinek DF (2006) A role for BLyS in the activation of innate immune cells. Blood 108: 2687-2694.
33. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, et al. (2009) BLymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol 82: 267-276.
34. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, et al. (2006) Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 24: 983-987.
35. Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, et al. (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69: 4217-4224.
36. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697-1710.
37. Mackay F, Sierro F, Grey ST, Gordon TP (2005) The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8: 243-265.
38. Phillips TA, Ni J, Hunt JS (2001) Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines. Placenta 22: 663-672.
39. Phillips TA, Ni J, Hunt JS (2003) Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas. J Leukoc Biol 74: 81-87.
40. Guo WJ, Qu X, Yang MX, Zhang WD, Liang L, et al. (2008) Expression of BAFF in the trophoblast and decidua of normal early pregnant women and patients with recurrent spontaneous miscarriage. Chin Med J (Engl) 121: 309-315.
41. Australasian Society for the Study of Hypertension in Pregnancy (1993) Management of hypertension in pregnancy: executive summary. Med J Aust 158: 700-702.
42. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, et al. (2000) The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol 40: 133-138.
43. Holmen J, Midthjell K, Kruger Ø, Langhammer A, Holmen TL, et al. (2003) The Nord-Trøndelag Health Study 1995-1997 (HUNT2): Objectives, contents, methods and participation. Norwegian Journal of Epidemiology 13: 19-32.
44. Fenstad MH, Johnson MP, Loset M, Mundal SB, Roten LT, et al. (2010) STOX2 but not STOX1 is differentially expressed in decidua from preeclamptic women. Mol Hum Reprod;DOI: 10.1093/molehr/gaq064.
45. Moses EK, Johnson MP, Tommerdal L, Forsmo S, Curran JE, et al. (2007) Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol 198: 336.e1-336.e5.
46. Gifford RW, Augusta PA, Cunningham G, et al. (2000) Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183.
47. Wingender E (2008) The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform 9: 326-332.
48. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, et al. (2010) JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 38: D105-D110.
49. Aas PA, Pena-Diaz J, Liabakk NB, Krokan HE, Skorpen F (2009) Overexpression of transcription factor AP-2 stimulates the PA promoter of the human uracil-DNA glycosylase (UNG) gene through a mechanism involving derepression. DNA Repair (Amst) 8: 822-833.
50. Sobel E, Lange K (1996) Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. Am J Hum Genet 58: 1323-1337.
51. Almasy L, Blangero J (1998) Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet 62: 1198-1211.
52. Blangero J, Goring HH, Kent JW Jr., Williams JT, Peterson CP, et al. (2005) Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol 77: 541-559.
53. Abecasis GR, Cookson WO, Cardon LR (2000) Pedigree tests of transmission disequilibrium. Eur J Hum Genet 8: 545-551.
54. Boerwinkle E, Chakraborty R, Sing CF (1986) The use of measured genotype information in the analysis of quantitative phenotypes in man. I. Models and analytical methods. Ann Hum Genet 50: 181-194.
55. Duggirala R, Williams JT, Williams-Blangero S, Blangero J (1997) A variance component approach to dichotomous trait linkage analysis using a threshold model. Genet Epidemiol 14: 987-992.
56. Moskvina V, Schmidt KM (2008) On multiple-testing correction in genomewide association studies. Genet Epidemiol 32: 567-573.
57. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, et al. (2003) MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31: 3576-3579.
58. Ryan AK, Rosenfeld MG (1997) POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev 11: 1207-1225.
59. Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO (1994) Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell 77: 21-32.
60. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, et al. (2006) TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: D108-D110.
61. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF, et al. (2009) Inflammation and pregnancy. Reprod Sci 16: 206-215.
62. Hatada EN, Do RK, Orlofsky A, Liou HC, Prystowsky M (2003) NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol 171: 761-768.
63. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3: 822-829.
64. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, et al. (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
65. Sargent IL, Borzychowski AM, Redman CW (2006) Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online 13: 680-686.
66. Hiby SE, Walker JJ, O'shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A (2004) Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 200: 957-965.
67. Santoni A, Zingoni A, Cerboni C, Gismondi A (2007) Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells. Am J Reprod Immunol 58: 280-288.
68. Shan X, Chen L, Cao M, Xu L, Zhang S (2006) Effects of human soluble BAFF synthesized in Escherichia coli on CD4+ and CD8+ T lymphocytes as well as NK cells in mice. Physiol Res 55: 301-307.
69. Zhang W, Wen L, Huang X, Liang J, Gao W, et al. (2008) hsBAFF enhances activity of NK cells by regulation of CD4(+) T lymphocyte function. Immunol Lett 120: 96-102.
70. Costa-Rodriguez EV, Craxton A, Hendricks DW, Merino MC, Montes CL, et al. (2007) BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur J Immunol 37: 990-1000.
71. Xu W, Santini PA, Matthews AJ, Chiu A, Plebani A, et al. (2008) Viral doublestranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol 181: 276-287.
72. Erridge C (2010) Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
73. Conde-Agudelo A, Villar J, Lindheimer M (2008) Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 198: 7-22.
74. Riley JK, Nelson DM (2009) Toll-like Receptors in Pregnancy Disorders and Placental Dysfunction. Clin Rev Allergy Immunol. DOI: 10.1007/s12016-009-8178-2.
75. Schmidt D, Wilson MD, Ballester B, Schwalie PC, Brown GD, et al. (2010) Fivevertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding. Science 328: 1036-1040.
76. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, et al. (2005) The transcriptional landscape of the mammalian genome. Science 309: 1559-1563.
77. Babu MM, Luscombe NM, Aravind L, Gerstein M, Teichmann SA (2004) Structure and evolution of transcriptional regulatory networks. Curr Opin Struct Biol 14: 283-291.
78. Masters JR (2002) HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2: 315-319.
79. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, et al. (2005) Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 26: 495-502.
80. Schork NJ, Murray SS, Frazer KA, Topol EJ (2009) Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 19: 212-219.
81. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118: 1590-1605.
82. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81: 873-883.
83. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
84. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA (2007) Genetics of preeclampsia: paradigm shifts. Hum Genet 120: 607-612.
85. Havill LM, Dyer TD, Richardson DK, Mahaney MC, Blangero J (2005) The quantitative trait linkage disequilibrium test: a more powerful alternative to the quantitative transmission disequilibrium test for use in the absence of population stratification. BMC Genet 6 Suppl 1: S91.